A dummy RESTful API built with Flask for an attendance management system. Uses fixed/mock data instead of a real database to simulate attendance tracking for employees and managers.

Abstract: Today’s cloud native applications are often built using a service-oriented architecture supported by many microservices hosted using serverless Function-as-a-Service (FaaS) platforms. The ...

Two years after revamping its developer programs and pricing, X is expanding the closed beta of a pay-per-use plan for its API to more developers. The social network is accepting applications from ...

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...

Bitdefender, a global cybersecurity leader, today announced outstanding results in the AV-Comparatives Endpoint Prevention and Response (EPR) Comparative Report 2025. The independent assessment ...

INNSBRUCK, Austria, Sept. 22, 2025 /CNW/ -- AV-Comparatives, the leading independent cybersecurity testing lab, today announced the results of its 2025 Endpoint Prevention and Response (EPR) Test, ...

Cyber threats and attacks like ransomware continue to increase in volume and complexity with the endpoint typically being the most sought after and valued target. With the rapid expansion and adoption ...

As IDC notes in their report, the endpoint security market “is growing in response to an increasingly sophisticated threat” powered by AI. Global enterprises like Crocs, Victorionox, and Del Monte ...

Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...

In 2015 I founded a cybersecurity testing software company with the belief that automated penetration testing was not only possible, but necessary. At the time, the idea was often met with skepticism, ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...